临床荟萃

• 专题 • 上一篇    下一篇

血必净联合乌司他丁治疗脓毒症诱导急性呼吸窘迫综合征的效果观察#br#

  

  1. 邢台市人民医院 急诊科,河北 邢台  054001
  • 出版日期:2018-07-05 发布日期:2018-08-06
  • 通讯作者: 通信作者:赵麦良,Email:zhaomailiang719@163.com
  • 作者简介:张延威, 河北省邢台县人,副主任医师,硕士研究生,研究方向:急危重症。
  • 基金资助:
    河北省中医药管理局科研计划项目(冀中医药2015315)

Effect of Xuebijing  injection combined with ulinastatin on sepsis induced ARDS patients

  1. Department of Emergency,  Xingtai People's Hospital,  Xingtai  054001, China
  • Online:2018-07-05 Published:2018-08-06
  • Contact: Corresponding author: Zhao Mailiang, Email:zhaomailiang719@163.com

摘要: 目的 探讨血必净联合乌司他丁治疗脓毒症诱导的急性呼吸窘迫综合征(ARDS)的疗效。方法 选取2014年5月至2016年7月在医院接受治疗的脓毒症诱导的ARDS患者60例,并将其随机分为观察组与对照组,每组30例,对照组采用乌司他丁进行治疗,观察组在对照组的基础上联合血必净进行治疗,使用序贯器官衰竭评分(SOFA)、急性生理学与慢性健康状况评分系统(APACHEⅡ)评分等进行分析,分析比较两组化验指标情况和临床疗效。结果 观察组降钙素原(PCT)、B型脑钠肽(BNP)、C反应蛋白(CRP)等化验指标明显低于对照组(P<0.05);观察组有创通气时间、EICU住院时间等明显短于对照组(P<0.05),两组普通病房住院时间无明显差异(P>0.05);观察组28天病死率为3.3%,明显低于对照组(10.0%),但是差异无统计意义(P>0.05)。结论 血必净联合乌司他丁治疗脓毒症诱导的ARDS疗效显著,降低了并发症的发生率,提高了治愈率,临床上值得推广应用。

关键词: 脓毒症, 乌司他丁, 血必净, 呼吸窘迫综合征,  , 成人

Abstract: Objective  To explore the efficacy of Xuebijing injection combined with ulinastatin in the treatment of acute respiratory distress syndrome (ARDS) induced by sepsis. Methods  A total of 60 patients with ARDS induced by sepsis from May 2014 to July 2016 were randomly divided into  observation group (n=30)  and control group(n=30). The patients in control group were treated with ulinastatin, and those in observation group were treated with Xuebijing on the basis of control group. The SOFA score and the APACHE Ⅱ score were used to analyze and compare the test indexes and clinical efficacy of the two groups. Results  The PCT,  BNP and CRP in observation group were significantly lower than those in control group(P<0.05). The time of invasive ventilation and EICU in observation group were significantly shorter than that in control group. The 28day mortality rate in observation group were significantly lower than that of control group(3.3% vs 10.0%, P>0.05). There was no significant difference in hospitalization time in general  ward between two groups of  patients (P>0.05).Conclusion  Xuebijing combined with ulinastatin is effective in the treatment of patients with ARDS induced by sepsis. It reduces the incidence of complications and improves the cure rate of patients,  worth popularizing in clinical practice.

Key words: sepsis; ulinastatin, xuebijing, respiratory distress syndrome, , adult